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Mycobacterium tuberculosis infection continues to cause substantial human suffering. New chemotherapeutic strategies, which
require insight into the pathways essential forM. tuberculosis pathogenesis, are imperative. We previously reported that deple-
tion of the CarD protein in mycobacteria compromises viability, resistance to oxidative stress and fluoroquinolones, and patho-
genesis. CarD associates with the RNA polymerase (RNAP), but it has been unknown which of the diverse functions of CarD are
mediated through the RNAP; this questionmust be answered to understand the CarDmechanism of action. Herein, we describe
the interaction between theM. tuberculosis CarD and the RNAP  subunit and identify point mutations that weaken this inter-
action. The characterization of mycobacterial strains with attenuated CarD/RNAP  interactions demonstrates that the CarD/
RNAP association is required for viability and resistance to oxidative stress but not for fluoroquinolone resistance. Weakening
the CarD/RNAP interaction also increases the sensitivity of mycobacteria to rifampin and streptomycin. Surprisingly, deple-
tion of the CarD protein did not affect sensitivity to rifampin. These findings define the CarD/RNAP interaction as a new target
for chemotherapeutic intervention that could also improve the efficacy of rifampin treatment of tuberculosis. In addition, our
data demonstrate that weakening the CarD/RNAP  interaction does not completely phenocopy the depletion of CarD and sup-
port the existence of functions for CarD independent of direct RNAP binding.
At least 30% of the world’s population is infected with latentMycobacterium tuberculosis, which in some individuals will
reactivate and cause 1.4 million deaths per year (26). An initial
infection with M. tuberculosis occurs when droplet nuclei are in-
haled into the pulmonary alveoli, where they are phagocytosed by
cells of the innate immune system (11). Macrophages, lympho-
cytes, and fibroblasts aggregate around the infected cells to form a
granuloma. Within the granuloma, the infected macrophages are
activated to destroy the bacteria with which they are infected (12).
The infected cells restrain mycobacteria from proliferating by im-
posing an arsenal of oxidative stress, hypoxia, acid stress, geno-
toxic stress, cell surface stress, and starvation (reviewed in refer-
ence 21). Despite this onslaught of attacks, M. tuberculosis is able
to persist for the lifetime of the host, indicating that this path-
ogen has substantial molecular mechanisms for resisting host de-
fenses.
M. tuberculosis resists elimination not only by the host’s immu-
nity but also by antimicrobial agents that are highly active against
M. tuberculosis in vitro, but only slowly sterilize M. tuberculosis
infection. Although active infection with drug-susceptible M. tu-
berculosis can be treated with multidrug antibiotic therapy, the
core of which consists of isoniazid, rifampin, and pyrazinamide,
the shortest antibiotic regimens that will achieve a reliable clinical
cure of active M. tuberculosis infection are 6 months in duration.
Significant investment in programs, like the Stop TB Strategy pro-
gram (25), for reducing tuberculosis (TB) incidence and mortality
have made some progress in decreasing the per capita TB rates.
Unfortunately, the prevalence of multidrug-resistant (MDR)
strains (resistant to the first-line therapies rifampin and isonia-
zid), which constituted 4.9% of TB cases in 2007, has caused grow-
ing recognition that the achievement of program goals may not be
possible with currently available tools. The inadequacies of pres-
ent tuberculosis therapies demand the discovery of new agents to
treat M. tuberculosis infection, which requires insight into the
pathways involved in M. tuberculosis pathogenesis.
During earlier investigations aimed at better understanding
mycobacterial stress responses, we identified CarD as a highly ex-
pressed bacterial protein that is also transcriptionally induced by
multiple types of stress (22). Efforts to delete the carD gene in M.
tuberculosis andMycobacterium smegmatiswere unsuccessful, sug-
gesting that CarD may be essential for viability, a suspicion that
was confirmed by the construction of depletion strains (22). Tran-
sient depletion of CarD revealed that cells lacking CarD are sensi-
tive to being killed by reactive oxygen species, ciprofloxacin, and
starvation. M. tuberculosis bacilli depleted for CarD are also un-
able to replicate and persist in mice. Therefore, the CarD protein is
a very attractive drug target, and the development of assays for
screening for chemical inhibitors of CarD requires characteriza-
tion of the essential functions and mechanisms of action of this
protein.
Microarray analyses revealed global changes in the transcrip-
tional profiles of mycobacteria during CarD depletion (22). Fur-
thermore, mycobacterial CarD was shown to associate with RNA
polymerase (RNAP). These findings led us to hypothesize that
CarD might be essential due to its ability to influence gene expres-
sion through direct contact with RNAP. Here we investigate this
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hypothesis and establish that disrupting the interaction between
CarD and the  subunit of RNAP has significant effects on myco-
bacterial survival, resistance to stress, and pathogenesis in murine
tissues. In addition, we discovered distinct phenotypic differences
between depleting CarD and weakening the CarD/RNAP 1 in-
teraction, suggesting that CarD performs additional cellular func-
tions separate from that of binding the RNAP.
MATERIALS AND METHODS
Media and bacterial strains. (i) M. tuberculosis. All M. tuberculosis
strains were derived from the Erdman strain and were grown at 37°C in
7H9 (broth) or 7H10 (agar) (Difco) medium supplemented with 60 l/
liter oleic acid, 5 g/liter bovine serum albumin (BSA), 2 g/liter dextrose,
0.003 g/liter catalase (OADC), 0.5% glycerol, and 0.05% Tween 80
(broth). Gene switching was used to construct strains of mycobacteria
expressing different carD alleles and to test for their viability (17). Specif-
ically, the M. tuberculosis carD attB::tet-carD merodiploid strain (as de-
scribed previously [22]) was transformed with pDB19-Rv3583cWT,
pDB19-Rv3583cR25E, pDB19-Rv3583cR47E, or pDB19-Rv3583cR25E,R47E
(expresses wild-type M. tuberculosis CarD [CarDWT], CarDR25E,
CarDR47E, or CarDR25E,R47E, respectively, from a constitutive Pmyc1-tetO
promoter, zeocin resistant) to replace the pMSG430Rv3583c construct
(expresses M. tuberculosis CarD from a constitutive Pmyc1-tetO pro-
moter, kanamycin resistant) at the attB site ofM. tuberculosiscarD attB::
tet-carD (22). The transformants were selected on zeocin and confirmed
for the loss of the pMSG430Rv3583c construct by verifying their inability
to grow on kanamycin. The Rv3583c gene from each transformant was
sequenced to confirm the presence of the correct sequence. When positive
transformants were unattainable in M. tuberculosis carD attB::tet-carD
(as was the case for the pDB19-Rv3583cR25E and pDB19-Rv3583cR25E,R47E
transformations), these mutants were deemed nonviable. The M. tuber-
culosis carD attB::tet-carD strains transformed with pDB19-Rv3583cWT
and pDB19-Rv3583cR47E were named mgm3080 and mgm3081, respec-
tively. There is only a single copy of the carD gene in all strains of the
mycobacteria used in this paper.
(ii) M. smegmatis. All M. smegmatis strains were isogenic to mc2155
and were grown at 37°C in LB supplemented with 0.5% dextrose, 0.5%
glycerol, and 0.05% Tween 80 (broth). The M. smegmatis strains express-
ing either hemagglutinin (HA)-tagged or untagged CarDWT, CarDR25E, or
CarDR47E were engineered as described for the analogous M. tuberculosis
strains using pDB19 expression plasmids and the M. smegmatis carD
merodiploid carD attB::tet-carD strain (as described previously [22]).
The M. smegmatis carD attB::tet-carD strains transformed with pDB19-
Rv3583cWT, pDB19-Rv3583cR25E, and pDB19-Rv3583cR47E were named
mgm1849, csm3, and csm40, respectively. The M. smegmatis Tet-CarD
(mgm1703) and control (mgm1701) strains used for the CarD depletion
experiments were previously described (22). Rifampin-resistant M. smeg-
matis carD attB::tet-carD, RNAP S438F, and RNAP H442R strains were
isolated by plating on 200 g/ml of rifampin. To engineer M. smegmatis
RNAP S438F and RNAP H442R strains to express CarDWT or CarDR25E,
the rifampin-resistant mutants were transformed with pDB19-
Rv3583cWT or pDB19-Rv3583cR25E to replace the pMSG430smcarD con-
struct, as just described.
Antibiotics and chemicals. In mycobacteria, 20 g/ml kanamycin,
12.5g/ml zeocin, 50g/ml hygromycin, 20g/ml streptomycin (unless
otherwise indicated), and 50 ng/ml of anhydrotetracycline (ATc) were
used. H2O2 (Fisher Scientific) and rifampin (Sigma) were used at the
indicated concentrations.
Bacterial two-hybrid assays. Plasmids for the two-hybrid analyses
were created by the cloning of corresponding NotI/BamHI-digested PCR
products into either NotI/BamHI-digested pBRLN or pACCI32 (as
described in reference 15). The plasmid pACCI-Mt 1 encodes residues
1 to 236 of the bacteriophageCI protein fused to residues 52 to 178 of the
 subunit of M. tuberculosis RNAP fused to residues 379 to 440 of the 
subunit of M. tuberculosis RNAP via two glycine residues, under the con-
trol of the isopropyl--D-thiogalactopyranoside (IPTG)-inducible
lacUV5 promoter. The plasmids pBR-Mt CarD, pBR-Mt CarD(1 to
66), and pBR-Mt transcription-repair coupling factor (TRCF) encode
residues 1 to 248 of the Escherichia coli RNAP  subunit fused to full-
length M. tuberculosis CarD, residues 1 to 66 of M. tuberculosis CarD, or
residues 513 to 653 of M. tuberculosis TRCF, respectively, under the con-
trol of tandem lpp and IPTG-inducible lacUV5 promoters. The indicated
amino acid substitutions were introduced into pACCI-Mt 1 and
pBR-CarD(1 to 66) by PCR. The plasmid pBR encodes the wild-type 
subunit and the plasmid pACCI encodes the bacteriophage CI protein.
FW102 F= OL2-62 reporter strain cells (6) that contained the test pro-
moter placOL2-62 driving the expression of a linked lacZ gene on an F=
episome were cotransformed with the indicated pAC- and pBR-derived
plasmids. Individual transformants were selected and grown in LB sup-
plemented with carbenicillin (100 g/ml), chloramphenicol (25 g/ml),
and kanamycin (50 g/ml). The plasmids directed the synthesis of the
fusion proteins under the control of IPTG-inducible promoters, and the
cells were grown in the presence of 5 M IPTG. -Galactosidase assays
were performed as described in reference 23 using microtiter plates and a
microtiter plate reader. Miller units were calculated as described in refer-
ence 23.
Antibiotic survival assays. For the zone of inhibition assays, 500l of
a log-phase culture was plated on 7H10 agar. A single 6-mm disk (Sigma)
was placed in the middle of the freshly plated bacterial lawn, and 5 l of
either 200 mg/ml streptomycin or 50 mg/ml isoniazid (INH) was spotted
on the disk. Water was spotted on a disk on a separate plated bacterial
lawn as a control. The plates were then incubated for 2 days before the
radius of the zone of inhibition was measured. For transient treatment in
liquid culture assays, log-phase cultures in LB broth for M. smegmatis or
7H9 broth for M. tuberculosis were treated with an antibiotic or H2O2 at
the stated concentrations. As done previously (22), M. smegmatis cultures
were treated for 1 or 2 h, which was adequate in M. smegmatis for us to see
an effect of each treatment in wild-type controls. When we tried this same
period of time for transient treatment in M. tuberculosis cultures, we ob-
served no effects on the survival of wild-type M. tuberculosis after 2 h. By
performing a time course, we determined that 75 h of H2O2 or rifampin
treatment in M. tuberculosis cultures was adequate to detect a measurable
effect of treatment in wild-type controls. The dilutions were made directly
from the treated cultures, and 5 l of each dilution was spot plated. We
have performed similar experiments by centrifuging treated cultures and
washing the cell pellets with phosphate-buffered saline (PBS) before plat-
ing dilutions and saw no difference in the rates of survival. Therefore, we
chose not to wash the treated cells to avoid the added stress of centrifuga-
tion.
Western blotting and immunoprecipitation. For immunoprecipita-
tion, 50-ml cultures were washed and lysed in 500 l of NP-40 buffer (10
mM sodium phosphate [pH 8.0], 150 mM NaCl, 0.25% NP-40, and Roche
Complete protease inhibitor cocktail) by bead beating. Twenty-five mi-
croliters of lysate was used for the input sample, and the rest was added to
monoclonal anti-HA agarose (Sigma) and rotated overnight at 4°C. The
matrix was washed 3 times with NP-40 buffer, and immunoprecipitated
protein complexes were eluted with 50 mM Tris-HCl (pH 7.5), 50 mM
NaCl, 500 g/ml HA peptide (Roche), and protease inhibitors. For the
Western blot analyses, CarD HA and RNAP were detected using mouse
monoclonal antibodies specific for HA (Sigma) and RNAP  (clone
8RB13; Neoclone, Madison, WI), respectively. A rabbit polyclonal anti-
body to CarD (22) was used to detect the CarD protein in the depletion
experiments shown in Fig. 5, and a monoclonal antibody to CarD (clone
10F05; Memorial Sloan-Kettering Cancer Center Monoclonal Antibody
Core Facility) was used to detect CarD in the depletion experiments
shown in Fig. 6.
Animal infections. Before infection, exponentially replicating M. tu-
berculosis mgm3080 (CarDWT) and mgm3081 (CarDR47E) strains were
washed in PBS plus 0.05% Tween 80 and sonicated to disperse clumps.
Eight- to nine-week-old female C57BL/6 mice (Jackson Laboratory) or
Weiss et al.
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H2K gp91phox/ mice (kindly provided by Kathy Frederick and Emil
Unanue) were exposed to 8  107 CFU of the appropriate strain in an
inhalation exposure system (Glas-Col) that delivers 100 bacteria per ani-
mal. The bacterial burden was determined by plating serial dilutions of
lung and spleen homogenates onto 7H10 agar plates. The plates were
incubated at 37°C in 5% CO2 for 3 weeks prior to counting colonies. All
procedures involving animals were conducted according to the National
Institutes of Health (NIH) guidelines for the housing and care of labora-
tory animals, and they were performed in accordance with institutional
regulations after protocol review and approval by the Institutional Animal
Care and Use Committee of the Washington University in St. Louis
School of Medicine (protocol 20100190, Analysis of Mycobacterial Patho-
genesis). Washington University is registered as a research facility with
the United States Department of Agriculture and is fully accredited by the
American Association of Accreditation of Laboratory Animal Care. The
Animal Welfare Assurance documentation is on file with the Office for
Protection from Research Risks of the NIH. All animals used in these
experiments were subjected to no or minimal discomfort. All mice were
euthanized by CO2 asphyxiation, which is approved by the American
Veterinary Medical Association Panel on Euthanasia.
RESULTS
Single point mutations in the CarD RID protein and RNAP 1
domain disrupt their interaction. The N terminus of the CarD
protein displays amino acid sequence similarity to that of the
RNAP interaction domain (RID) of the TRCF (the product of the
mfd gene). We previously reported that Thermus thermophilus
CarD interacts with the same region at the N terminus of the
RNAP  subunit (the 1 domain) as the T. thermophilus TRCF
(22, 24). Studies of Myxococcus xanthus proteins have reported
similar findings (10). To establish whether M. tuberculosis CarD
also interacts with the 1 domain of M. tuberculosis RNAP, we
used a bacterial two-hybrid assay (Fig. 1A) (7, 8). In this assay,
contact between a protein domain fused to a component of RNAP
(here, the  subunit) and a partner protein fused to a DNA-bind-
ing protein (here, the CI protein of bacteriophage ) activates
transcription of a lacZ reporter gene under the control of a test
promoter bearing an upstream recognition site for the DNA-
binding protein (in this case, a  operator). We fused either the
full-length M. tuberculosis CarD or the CarD RID (residues 1 to
66) to the subunit N-terminal domain (-NTD), replacing the
subunit C-terminal domain, and the M. tuberculosis 1 domain
was fused to the CI protein of bacteriophage. We detected a large
increase in transcription from the test promoter when we induced
the synthesis of the CI-1 fusion protein along with either the
full-length CarD  fusion protein or the CarD RID  fusion pro-
tein (Fig. 1B). This demonstrated thatM. tuberculosisCarD, via its
N-terminal RID domain, interacts with the 1 domain of M. tu-
berculosis RNAP. Although the mode of binding of CarD and
TRCF to RNAP is the same, we have previously shown that these
proteins have distinct cellular functions (22).
Having established that we could use the two-hybrid assay to
detect the M. tuberculosis CarD/1 interaction, we next sought to
determine whether M. tuberculosis CarD and TRCF interact with
the RNAP  subunit in a similar manner. The X-ray crystal struc-
ture of the T. thermophilus TRCF RID complexed with the Ther-
mus aquaticus RNAP 1 domain (24) revealed that T. thermophi-
lus TRCF RID R341 forms a hydrogen bond with RNAP 1 Q99,
as well as polar interactions with RNAP 1 E110. The RNAP 1
residues I108 and K109 are also central to the protein/protein
interface, making extensive van der Waals contacts with the TRCF
RID (24).T. thermophilusTRCF RID R341 andT. aquaticusRNAP
1 E110 correspond toEscherichia coliTRCF RID L499 and RNAP
1 E119, respectively, which were both previously demonstrated
to be important for the interaction between the TRCF and RNAP
 in E. coli (6, 20).
To extrapolate these structural insights to mycobacteria, we
aligned the T. aquaticus 1 sequence with the 1 domain from M.
tuberculosis and concluded that residues E138, I147, K148, and
S149 of M. tuberculosis RNAP 1 correspond to residues Q99,
I108, K109, and E110 in T. aquaticus RNAP 1, respectively (24)
(Fig. 1C). To determine whether these residues were critical to the
TRCF RID/1 interaction in mycobacteria, we performed bacte-
rial two-hybrid experiments between the M. tuberculosis TRCF
RID and RNAP 1 harboring one or more mutations in these
residues. The M. tuberculosis RNAP 1E138R and RNAP 1I147A
substitutions had dramatic effects on the strength of the interac-
tion with the TRCF RID (Fig. 1D). In contrast, alanine substitu-
tions at M. tuberculosis RNAP 1 K148 or S149 did not inhibit the
association with the TRCF RID.
We next used the bacterial two-hybrid assay to determine if the
same mutations in M. tuberculosis RNAP 1 that weakened the
interaction with the TRCF RID would also affect the association
with the M. tuberculosis CarD RID (residues 1 to 66). Similar to
their effect on the TRCF RID interaction, the RNAP 1E138R and
RNAP 1I147A substitutions weakened the interaction with the
CarD RID (Fig. 1D). The 1K148A and 1S149A substitutions in the
M. tuberculosis RNAP 1 domain also weakened CarD RID bind-
ing, although these same mutations were inconsequential for
TRCF RID binding. Therefore, CarD and TRCF associate with the
RNAP  subunit in similar manners, although with subtle differ-
ences.
To identify residues in CarD that are important for the CarD/
RNAP interaction, we generated a homology model of the M.
tuberculosis CarD RID interacting with the RNAP 1 domain
based on the structure of the Thermus sp. TRCF RID/RNAP 1
complex (Protein Data Bank accession number 3MLQ [24]) (Fig.
1E). According to our modeled structure, M. tuberculosis CarD
RID R25 interacts with M. tuberculosis RNAP 1 E138 (homolo-
gous to the Thermus sp. TRCF-RID R341:RNAP 1 Q99 interac-
tion) (Fig. 1E). In addition to M. tuberculosis CarD RID R25, the
model structure predicts that another arginine, that at position 47,
would interact with M. tuberculosis RNAP 1 E138. We made
arginine-to-glutamic acid substitutions at position 25 or 47 in
our CarD RID bacterial two-hybrid constructs to test the ef-
fects of these mutations on the interaction between CarD and
RNAP 1. Either substitution on its own greatly diminished
the ability of these proteins to interact, with CarD RIDR25E
having the most severe effect (Fig. 1F). A double point mutation
(CarD RIDR25E,R47E) completely abolished the interaction. We
were able to fully suppress the effect of the CarD RIDR47E muta-
tion with the RNAP 1E138R substitution, confirming the specific
interaction between these two residues predicted from the struc-
tural model (Fig. 1F). The RNAP 1E138R mutation did not sup-
press the effects of the CarD RIDR25E mutation, suggesting that the
CarD RIDR25E substitution disrupts additional contacts between
these proteins. This is supported by theThermus sp. TRCF RID/1
structure, where Thermus sp. TRCF RID R341 (corresponding to
M. tuberculosis CarD RID R25) interacts with multiple residues in
the 1 subunit (24).
The CarD/RNAP1 interaction is critical for mycobacterial
survival. Having identified the amino acid substitutions that dis-
CarD/RNAP Interaction Required for Pathogenesis
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FIG 1 M. tuberculosis CarD and TRCF interact with the RNAP 1 domain. (A) The cartoon depicts how contact between a protein domain (X) fused to the 
subunit of the E. coli RNAP and a partner domain (Y) fused to a DNA-binding protein (the CI protein of bacteriophage ) activates transcription from the test
promoter placOL2-62, which bears an upstream recognition site for CI (OL2). (B) Results of -galactosidase assays performed with FW102 OL2-62 cells that
contained two compatible plasmids: one that encoded M. tuberculosis CarD (black bars) or CarD RID (residues 1 to 66; gray bars) protein fused to  or unfused
to  (designated ; white bar) and another that encoded the M. tuberculosis RNAP 1 protein (residues 52 to 178-GG-379 to 440) fused to CI or CI itself
(designated). (C) Alignments of theT. thermophilusTRCF RID region with theM. tuberculosisCarD RID region andT. aquaticusRNAP1 withM. tuberculosis
RNAP 1. Thermus sp. residues are based on alignments shown in Fig. 2 of reference 24. An asterisk indicates a fully conserved residue, a colon indicates
conservation between groups of strongly similar properties, and a period indicates conservation between groups of weakly similar properties. The residues
highlighted in red are listed in the table as residues in M. tuberculosis that correspond to the amino acids previously characterized in Thermus sp. to participate
in the interaction between TRCF and RNAP 1 (24). (D) Results of -galactosidase assays performed with FW102 OL2-62 cells that contained two compatible
plasmids: one that encodedM. tuberculosisTRCF RID (residues 513 to 653; black bars) or theM. tuberculosisCarD RID (residues 1 to 66; gray bars) protein fused
to  and another that encoded the indicated M. tuberculosis RNAP 1 protein (residues 52 to 178-GG-379 to 440) fused to CI or CI itself (designated). (E)
Homology model (19) of M. tuberculosis CarD RID with M. tuberculosis RNAP 1 based on the crystal structure of the T. thermophilus TRCF RID with T.
aquaticus RNAP 1 (24). Proteins are shown as backbone ribbons, with the CarD RID in light pink and RNAP 1 in light cyan. The side chains of residues at the
interaction interface discussed in the text are shown (CarD RID, magenta; RNAP 1, cyan). (F) Results of -galactosidase assays performed with FW102 OL2-62
cells that contained two compatible plasmids: one that encoded the indicated M. tuberculosis CarD RID (residues 1 to 66) protein fused to  and another that
encoded the indicated M. tuberculosis RNAP 1 protein (residues 52 to 178-GG-379 to 440) fused to CI. All bar graphs show the averages of three independent
measurements and standard deviations.
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rupt the CarD/RNAP1 interaction, we next sought to determine
whether disrupting this interaction would affect mycobacterial
viability. We chose to examine only the effects of point mutations
in CarD and not in RNAP 1 for our assays in mycobacteria to
avoid interfering with the TRCF/RNAP interaction. Thus, we at-
tempted to replace the carD gene of M. smegmatis and M. tuber-
culosis with the alleles encoding CarDR25E, CarDR47E, or the
CarDR25E,R47E double mutant using a gene-switching technique
(17). We successfully replaced the wild-type (WT) carD gene inM.
smegmatis with an allele expressing CarDR25E or CarDR47E and in
M. tuberculosiswith an allele expressing CarDR47E (Fig. 2A). Using
the gene-switching technique, we were unable to engineer a viable
CarDR25E,R47E double mutant, which is incapable of interacting
with RNAP 1 (Fig. 1F), indicating that the interaction between
CarD and the RNAP is important for viability (Fig. 2A). In fact,
even the CarDR25E substitution was unattainable in M. tuberculo-
sis, again emphasizing that attenuating the CarD/RNAP 1 inter-
action compromises survival.
We measured growth curves of the viableM. smegmatis andM.
tuberculosis mutants and found that as the interaction of CarD
with RNAP was weakened, the growth rate also decreased (Fig. 2B
and C). Based on five replicate experiments, the doubling time of
the M. smegmatis CarDR25E mutant was 1.198 times (standard
deviation, 0.067) slower than that of the wild-type control strain.
Likewise, the doubling time of the M. tuberculosis CarDR47E mu-
tant was 1.181 times (standard deviation, 0.001) slower than that
of the wild-type control strain in three replicate experiments. The
phenotypes associated with interfering with the CarD/RNAP 
interaction were dramatically more severe in M. tuberculosis than
inM. smegmatis. This was evidenced by the decrease in the growth
rate of the M. tuberculosis CarDR47E mutant compared to that in
the wild-type CarD-expressing strain, while in M. smegmatis the
analogous mutant grew at wild-type rates. These findings suggest
that an optimal interaction between CarD and RNAP  is more
critical for the growth ofM. tuberculosis than ofM. smegmatis, and
further comparison of these bacteria may shed light on the func-
tions of CarD.
Consistent with the bacterial two-hybrid results, coimmuno-
precipitation experiments in mycobacteria demonstrated that
even though the intracellular levels of CarD and RNAP  were
unchanged, CarDR25E and CarDR47E mutants coprecipitated less
RNAP  than CarDWT (Fig. 2D). These data confirmed that the
R25E and R47E substitutions in CarD compromise the association
with RNAP and emphasize the importance of the CarD/RNAP 1
interaction for mycobacterial growth and survival. In light of these
findings, we predict that small molecules that interfere with the
CarD/RNAP1 interaction could be promising novel chemother-
apies for killing M. tuberculosis.
The CarD/RNAP1 interaction is essential for the ability of
mycobacteria to resist killing by reactive oxygen species.During
infection, M. tuberculosis must withstand an arsenal of host-de-
rived stresses, including the production of reactive oxygen species
by the oxidative burst (5). We previously showed that depleting
CarD dramatically increases the sensitivity of mycobacteria to ox-
idative stress (22). To test whether weakening the CarD/RNAP 1
interaction would have a similar effect, log-phase cultures of M.
smegmatis and M. tuberculosis strains expressing different carD
alleles were treated with either 10 mM or 25 mM H2O2 before
dilutions were plated to count the surviving CFU (Fig. 3). All CarD
mutants were more sensitive to H2O2 treatment than were the wild
type, with the M. smegmatis CarDR25E mutant being more sensitive
than was M. smegmatis expressing CarDR47E, demonstrating that the
FIG 2 Weakening the interaction between CarD and the RNAP compromises the growth of mycobacteria. (A) Table of mycobacterial strains engineered by
replacing the CarDWT expression cassette with one that expresses the designated mutant and mutants that were unattainable by gene switching. The strength of
RNAP interaction is based on the bacterial two-hybrid results shown in Fig. 1. (B and C) Representative growth curve from 5 replicates of M. smegmatis (B) and
3 replicates of M. tuberculosis (C) carD attB::tet-carD strain expressing CarDWT, CarDR25E, or CarDR47E. (D) Immunoprecipitation experiments with a
monoclonal antibody specific for HA in the M. smegmatis carD attB::tet-carD strain expressing untagged CarDWT (lane 1, also expresses HA peptide),
CarDWT-HA (lane 2), CarDR25E-HA (lane 3), or CarDR47E-HA (lane 4). Inputs (before immunoprecipitation) and eluates were analyzed by Western blotting with
antibodies specific for either RNAP  or HA.
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strength of the CarD/RNAP1 interaction directly correlates to sur-
vival in the presence of reactive oxygen species (Fig. 3).
Weakening the CarD/RNAP 1 interaction affects the
pathogenesis ofM. tuberculosis inmurine tissues.CarD is essen-
tial for acute and persistentM. tuberculosis infections in mice (22).
We hypothesized that the optimal association of CarD with RNAP
would be particularly critical for mycobacteria to resist host-in-
flicted oxidative stress during infection, and disrupting the inter-
action could compromise M. tuberculosis survival in the host. To
investigate the effect of weakening the association of CarD with
RNAP on M. tuberculosis pathogenesis, we infected C57BL/6 mice
with M. tuberculosis strains expressing either CarDWT or the
CarDR47E mutant. These strains showed similar virulence during
acute infection of the murine lungs (Fig. 4A). However, at 5 weeks
postinfection, which is early during a persistent infection, the bac-
terial titers of the M. tuberculosis CarDR47E mutant were a half-log
lower than those of the CarDWT-expressing bacteria in the lung
and were unable to persist at the same level as the CarDWT-ex-
pressing strain (Fig. 4A). The attenuation of the M. tuberculosis
CarDR47E strain was more dramatic in the spleens of infected mice,
FIG 3 Weakening the interaction between CarD and the RNAP compromises the survival of mycobacteria during oxidative stress. (A and B) Survival of M.
smegmatis strains during oxidative stress. The log-phaseM. smegmatiscarD attB::tet-carD strains expressing CarDWT, CarDR25E, or CarDR47E in LB were treated
for 1 h with either 10 mM or 25 mM H2O2. After treatment, dilutions were plated on LB. Panel A shows one such experiment, and B graphically represents survival
as a ratio of CFU in treated cultures to that in untreated cultures. (C) Survival of the M. tuberculosis strains during oxidative stress. The log-phase M. tuberculosis
carD attB::tet-carD strains expressing CarDWT or CarDR47E growing in 7H9 broth were treated for 75 h with 25 mM H2O2. After treatment, dilutions were plated
on 7H10 agar, and survival is graphically represented as the ratio of CFU in treated cultures to that in untreated cultures. The graphs in panels B and C show the
mean standard error of the mean (SEM), and each sample is represented by a black circle. The significance levels in panels B and C were determined by
calculating P values by Student’s t test; an asterisk indicates significance with a P value of	0.05, two asterisks indicate significance with a P value of	0.01, and
three asterisks indicate significance with a P value of	0.005.
FIG 4 The association of CarD with the RNAP is required for the persistence of M. tuberculosis in mice. (A and B) Pathogenesis of M. tuberculosis strains in
C57BL/6 mice. Shown are bacterial titers in the lungs (A) and spleens (B) of C57BL/6 mice infected with M. tuberculosis expressing either CarDWT (open circles)
or CarDR47E (open triangles). Each time point is the mean SEM of data from seven mice per strain, combined from two experiments. (C) Pathogenesis of M.
tuberculosis strains in H2K gp91phox/ mice. Shown is a graph of the total CFU in the lungs of gp91phox/ mice infected with 80 to 120 CFU of M. tuberculosis
expressing either CarDWT (black bars) or CarDR47E (gray bars) at 5 weeks postinfection. Data are means  SEM of results for three mice per strain. The
significance levels for data in all panels were determined as described for Fig. 3. NS, not significant.
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where the titer of the mutant was already a half-log lower than that
of the CarDWT-expressing bacteria by 3 weeks postinfection (Fig.
4B), despite identical levels between strains in the lungs at that
time point (Fig. 4A). In addition, the titer of the mutant was more
than a half-log lower than that of the CarDWT-expressing bacteria
by 5 weeks in the spleen (Fig. 4B), suggesting that weakening the
association of CarD with the RNAP causes a defect that is partic-
ularly detrimental to dissemination to or survival in the spleen.
Given that the R47E substitution in CarD only has partial effects
on RNAP binding (Fig. 1F and 2D) and that mutations that fur-
ther decrease the affinity of CarD to RNAP  are unattainable in
M. tuberculosis (Fig. 2A), we predict an even more dramatic atten-
uation in pathogenesis if the CarD/RNAP 1 association is more
severely inhibited.
Since we had observed that the M. tuberculosis strains express-
ing CarDR47E were more sensitive to oxidative stress (Fig. 3), one
possible cause for the attenuation of these strains is their inability
to resist the host oxidative burst. The phagocytic oxidative burst
requires the NADPH oxidase gp91phox and p47phox proteins to
produce superoxide. Infection of mice lacking the p47phox gene
with wild-type M. tuberculosis results in a significant increase in
bacterial growth over days 14 to 30 of infection, indicating that the
phagocytic oxidative burst is transiently important in controlling
infection (5). The infection of gp91phox/ mice (18) with M.
tuberculosis strains expressing either CarDWT or CarDR47E dem-
onstrated that the mutant was still attenuated for infection despite
the absence of the phagocytic oxidative burst (Fig. 4C), indicating
that the in vivo phenotype of the CarDR47E strain must also be due
to sensitization to additional host-derived stresses.
Compromising the CarD/RNAP 1 interaction increases ri-
fampin sensitivity in mycobacteria, whereas depleting CarD
does not. The interaction between CarD and the  subunit of
RNAP would be a novel target for tuberculosis treatment; how-
ever, it would not be the first time that the bacterial RNAP was
targeted. Rifampin, a potent, broad-spectrum antibiotic, is a key
component of antituberculosis therapy that binds the RNAP 
subunit within the DNA/RNA channel and is predicted to block
directly the path of the elongating RNA (3, 9). Although the ri-
fampin binding site is distinct from the binding site of CarD on the
 subunit, we were curious whether weakening the CarD/RNAP
interaction would affect the efficacy of rifampin treatment of my-
cobacteria. To test this, we transiently treated M. smegmatis and
M. tuberculosis strains expressing CarDWT, CarDR25E (M. smegma-
tis only), or CarDR47E (M. smegmatis and M. tuberculosis) with
rifampin and monitored survival by plating for CFU (Fig. 5A). In
both mycobacterial species, the strength of the CarD interaction
with RNAP directly correlated to survival during rifampin treat-
ment (Fig. 5A, B, and D), thus showing that weakening the asso-
ciation of CarD with RNAP increases the potency of rifampin. In
a similar experiment, we tested whether depleting CarDWT levels
made M. smegmatis more sensitive to rifampin treatment, and we
found that it did not (Fig. 5B and C). This implies that it is the
specific interference of the CarD/RNAP interaction that compro-
mises the bacteria’s survival during rifampin treatment.
Since we had shown that M. tuberculosis strains expressing
CarDR47E instead of CarDWT were more sensitive to transient
treatment with rifampin, we were curious how weakening the
CarD/RNAP interaction would affect the MIC of the rifampin
treatment of M. tuberculosis. To test the minimum concentration
of rifampin that is able to halt the growth of M. tuberculosis, we
plated dilutions of strains expressing CarDWT or CarDR47E onto
7H10 plates containing a range of rifampin concentrations (Fig.
5E). The MIC of the rifampin treatment ofM. tuberculosis express-
ing CarDWT was 
2 g/ml, which is comparable to published
values for wild-type strains (16). In contrast, the MIC of the ri-
fampin treatment of M. tuberculosis expressing CarDR47E was

0.8g/ml, and the survival of the CarDR47E-expressing strain in
the presence of 0.4 g/ml rifampin was 3 logs lower than that of
the CarDWT-expressing strains (Fig. 5E). These data show that
weakening the association of CarD with the RNAP decreases the
MIC of rifampin, suggesting that targeting the CarD/RNAP  in-
teraction could increase the efficacy of rifampin treatment. In ad-
dition, we predict that inhibiting the CarD/RNAP  interaction
more dramatically than the R47E mutation would further increase
the sensitivity to rifampin.
We had also previously shown that depleting CarD increased
the sensitivity of M. smegmatis to ciprofloxacin treatment (22). In
contrast, weakening theM. smegmatisCarD/RNAP1 interaction
had no effect on sensitivity to 10g/ml ciprofloxacin treatment in
2 h of transient-treatment liquid culture assays (data not shown).
Therefore, although depletion of CarDWT and weakening the
CarD/RNAP 1 interaction have similar effects on resisting reac-
tive oxygen species, these alterations of CarD function have dif-
ferent effects on the susceptibilities to rifampin and ciprofloxacin.
This raised the question of how CarD depletion and the CarD RID
mutants would affect the sensitivity of mycobacteria to other an-
tibiotics used to treatM. tuberculosis infection. To address this, we
examined CarD-mediated resistance to isoniazid (INH), pyrazin-
amide (PZA), and streptomycin inM. smegmatis. The depletion of
CarD or weakening of the CarD/RNAP interaction had no effect
on sensitivity to up to 8 mg/ml PZA in media at pH 5.2 in 2 h of
transient-treatment liquid culture assays and no reproducible ef-
fect on INH sensitivity in the disk zone of inhibition assays, tran-
sient-treatment liquid culture assays with up to 500 g/ml INH,
or MIC determination assays done by plating strains on 7H10 agar
containing INH (as done previously [14]) (data not shown).
However, we found that the M. smegmatis CarDR25E strain, as well
as a strain depleted for CarDWT, were significantly more sensitive
to streptomycin treatment than control strains in both the disk
zone of inhibition assays (Fig. 6A and B, CarDR25E only) and tran-
sient-treatment liquid assays (Fig. 6C to E, CarDR25E and CarD
depletion). Thus, the depletion of CarD and the weakening of the
CarD/RNAP association have the same effect on sensitivity to
streptomycin.
Rifampin resistance mutations in RNAP do not rescue the
sensitivity ofmycobacteria to weakening of the CarD/RNAP in-
teraction. Rifampin resistance is a characteristic of the MDR M.
tuberculosis strains, and almost all resistance mutations map to the
RNAP  subunit. Since we had observed that weakening the
CarD/RNAP interaction increased the sensitivity of mycobacteria
to rifampin, we tested if we could restore rifampin sensitivity in
resistant mutants by interfering with CarD’s association with the
RNAP. We selected for rifampin-resistant strains of M. smegmatis
on plates containing 200 g/ml of rifampin. We sequenced the
rpoB gene (encoding the RNAP  subunit) of the colonies that
grew and selected two strains with mutations in residues that have
been reported to be altered in clinical isolates of the MDR M.
tuberculosis: RNAP S438F and RNAP H442R (4, 13). These muta-
tions are predicted to block the rifampin binding pocket. Each
rifampin-resistant mutant was engineered to express either
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FIG 5 Weakening the interaction between CarD and the RNAP increases the sensitivity of mycobacteria to rifampin. (A and B) Survival of M. smegmatis strains
during transient rifampin treatment. The log-phase M. smegmatis carD attB::tet-carD strains expressing CarDWT, CarDR25E, or CarDR47E growing in LB were
treated for 1 h with 100 g/ml, 200 g/ml, or 500 g/ml rifampin before dilutions were plated to determine the surviving CFU. M. smegmatis Tet-CarD and
control strains were grown in LB without ATc for 13 h to deplete the carD transcript levels in Tet-CarD and treated for 1 h with 200g/ml or 500g/ml rifampin,
and dilutions were plated on LB plus ATc to determine the surviving CFU. (A) Representative experiment. (B) Survival as the mean ratio of CFU in treated
cultures to that in untreated cultures the SEM, with each sample represented by a black circle. (C) Western blot analysis of protein lysates from M. smegmatis
Tet-CarD and control strains grown in LB without ATc for 13 h to confirm depletion of CarD in Tet-CarD samples. RNAP  was detected in each sample as a
loading control. (D) Survival of M. tuberculosis strains during transient rifampin treatment. The M. tuberculosiscarD attB::tet-carD strains expressing CarDWT
or CarDR47E growing in 7H9 broth were transiently treated for 75 h with 200 g/ml of rifampin. After treatment, dilutions were plated on 7H10 plates, and the
survival was calculated as a ratio of CFU after treatment to that in untreated cultures. The graph shows the mean SEM of data from three experiments, with
each sample represented by a black circle. The significance levels in panels B and D were determined as described for Fig. 3. (E) Tenfold dilutions starting at 2.5
108 CFU ofM. tuberculosis strains expressing CarDWT or CarDR47E were plated on 7H10 plates containing 0.0, 0.1, 0.4, 0.8, or 2g/ml of rifampin. The plates were
incubated at 37°C for 6 weeks, and the MIC was defined as the lowest concentration of rifampin that inhibited all growth of the M. tuberculosis strain. The
significance levels for all panels were determined as described for Fig. 3.
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CarDWT or CarDR25E and treated with rifampin to test if they
retained rifampin resistance. Figure 7A shows that despite the
weaker association of CarD with RNAP, the RNAP S438F- and
RNAP H442R-expressing strains retained resistance to 500 g/ml
of rifampin. This indicated that these mutations still interfere with
the binding of rifampin, and therefore, the effects of the CarD-
RID mutants on rifampin sensitivity could not be observed.
The mutations in RNAP  that confer rifampin resistance may
alter the conformation of the RNAP and could potentially have
allosteric effects on the interactions of RNAP-associated factors,
like CarD. Thus, we inquired whether a rifampin resistance mu-
tation in RNAPwould affect the phenotypes of interference with
the CarD/RNAP interaction. To examine this, we measured the
growth rates and sensitivities to oxidative stress of theM. smegma-
tis rifampin-resistant mutants expressing either CarDWT or
CarDR25E. The effect on the growth rates in M. smegmatis rifam-
pin-resistant mutants varied based on the RNAP  mutation.
CarDWT- and CarDR25E-expressing strains in the RNAP S438F
mutant background grew at similar rates, where the average ratio
of CarDR25E to CarDWT doubling times was 0.988, with a standard
deviation of 0.047 (Fig. 7B). However, strains expressing CarDR25E
grew 1.229 times (standard deviation, 0.066) slower than did
CarDWT-expressing strains in the RNAP H442R background (Fig.
7C). In the presence of either rifampin-resistant mutation in
RNAP , the CarDR25E-expressing strains still showed increased
susceptibility to oxidative stress (Fig. 7D). This demonstrates that
rifampin-resistant mycobacterial strains are still compromised by
weakening the CarD/RNAP interaction.
DISCUSSION
CarD represents a new class of RNAP-binding proteins that are
absent from the model organism Escherichia coli but are ubiqui-
tous in mycobacteria and conserved in many other eubacteria.
Thus, our findings in mycobacteria expand the paradigms of tran-
scription regulation and stress responses that have been estab-
lished in model systems and then translate these processes to
pathogenesis. To gain clues into the possible functions of CarD,
our group and others have turned to the wealth of knowledge
regarding TRCF due to the similarity of the RNAP interaction
domains (RIDs) of these two proteins. Before our direct compar-
ison of the CarD RID/RNAP 1 and TRCF RID/RNAP 1 com-
plexes, the intricacies of these interactions would have been as-
sumed to be the same due to their shared interaction surface on
the RNAP. However, our analyses revealed subtle differences be-
tween the ways these proteins associate with RNAP1 that may be
relevant to their functional differences, strongly suggesting that
we cannot settle on the TRCF RID/RNAP 1 structure as an ab-
solute model for CarD’s interaction with the RNAP, and an anal-
ogous structure of CarD with RNAP1 is necessary to understand
fully the CarD/RNAP interaction and CarD function.
In our original report of mycobacterial CarD, we used a tetra-
cycline-inducible promoter system to deplete CarD transcript lev-
els (which resulted in lower CarD protein levels) to study the
effects of decreased CarD levels on the cell (22). The depletion of
CarD led to pleiotropic effects in mycobacteria, and until now it
was unknown what functions of CarD contributed to its essenti-
FIG 6 Weakening the interaction between CarD and the RNAP and depleting CarD increases sensitivity to streptomycin. (A and B) Survival of theM. smegmatis
strains during the disk zone of inhibition assays with streptomycin. Five hundred microliters of the log-phase M. smegmatis carD attB::tet-carD strains
expressing CarDWT or CarDR25E was plated on LB agar, and a disk spotted with 5 l of 200-mg/ml streptomycin was placed in the middle of the bacterial lawn.
(A) Representative experiment. (B) The radius of the zone of inhibition as the mean SEM of data from three biological replicates for each strain. (C and D)
Survival of M. smegmatis strains during transient streptomycin treatment. The log-phase M. smegmatis carD attB::tet-carD strains expressing CarDWT or
CarDR25E growing in LB were treated for 2 h with 10 g/ml streptomycin before the dilutions were plated to determine the surviving CFU. M. smegmatis
Tet-CarD and control strains were grown in LB without ATc for 13 h to deplete carD transcript levels in Tet-CarD and treated for 2 h with 10g/ml streptomycin,
and dilutions were plated on LB plus ATc to determine the surviving CFU. (C) Representative experiment. (D) Survival as the mean ratio of CFU in treated
cultures to that in untreated cultures  SEM, with each sample represented by a black circle. (E) Western blot analysis of protein lysates from M. smegmatis
Tet-CarD (lanes 2, 3, 5, 6, and 8) and control (lanes 1, 4, and 7) strain replicates grown in LB without ATc for 13 h to confirm the depletion of CarD in Tet-CarD
samples. The RNAP  subunit was detected in each sample as a loading control. The significance levels for all panels were determined as described for Fig. 3.
CarD/RNAP Interaction Required for Pathogenesis
October 2012 Volume 194 Number 20 jb.asm.org 5629
ality. Currently, the only known activity of CarD is binding the
RNAP through its N-terminal RID, but we have also shown that
this activity is not sufficient for CarD function, since the RID alone
cannot support mycobacterial viability (22). Thus, it was impor-
tant to investigate what roles of CarD are mediated through its
interaction with RNAP in order to begin to address the mecha-
nism of action of CarD. In this paper, we have isolated CarD point
mutants that do not change the abundance of the CarD protein
but instead decrease its affinity to the RNAP  subunit. This has
allowed us to examine functions of CarD that are specifically de-
pendent on the interaction with RNAP .
We have established that the interaction between CarD and the
RNAP  subunit is required for mycobacterial viability and viru-
lence and is thus a valid target for the development of screens for
the identification of small-molecule inhibitors. Small-molecule
inhibitors of proteins, like CarD, that are necessary for M. tuber-
culosis to tolerate stresses during infection would be promising
candidates for compromising the pathogen and potentially short-
ening the duration of therapy. In general, it is thought that a pro-
tein/protein interaction is not an ideal drug target compared to
the catalytic domain of an enzyme, but we believe that the sensi-
tivity of the CarD/RNAP interaction to single-residue changes
suggests that a small molecule could also interfere. The success of
rifampin is also an excellent example of the efficacy of targeting
the RNAP complex with antibiotics. Therefore, these studies pro-
vide the prelude to a new avenue of drug development involving
screens for chemical inhibitors of the CarD/RNAP interaction
that will not only be relevant to mycobacterial infections but could
also be important for diverse bacterial pathogens that encode
CarD homologs. In addition, we show that weakening the CarD/
FIG 7 Rifampin-resistant mutants are still sensitive to interference with the CarD/RNAP interaction. (A) Survival of M. smegmatis strains during rifampin
treatment. The M. smegmatis strains resistant to rifampin due to substitutions in RNAP  at either position S438 (S438F) or H442 (H442R) were engineered to
express either CarDWT or CarDR25E. The log-phase S438F CarDWT, S438F CarDR25E, H442R CarDWT, and H442R CarDR25E cultures in LB were treated for 1 h
with 500 g/ml in rifampin. After treatment, dilutions were plated on LB, and survival was determined as a ratio of CFU after treatment to that in untreated
cultures. The graph shows the mean SEM, and each sample is represented by a black circle. (B and C) Representative growth curves from 4 replicates each of
M. smegmatis S438F CarDWT (open circles), S438F CarDR25E (open squares), H442R CarDWT (closed circles), and H442R CarDR25E (closed squares) in LB. (D)
Survival of M. smegmatis strains during H2O2 treatment. The log-phase M. smegmatis 
S438F CarDWT, S438F CarDR25E, H442R CarDWT, and H442R CarDR25E
cultures were treated for 1 h with 25 mM H2O2. After treatment, dilutions were plated on LB, and survival was determined as a ratio of CFU after treatment to
that in untreated cultures. The graph shows the mean  SEM, and each sample is represented by a black circle. The significance levels were determined as
described for Fig. 3.
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RNAP interaction also increases the sensitivity of M. tuberculosis
to rifampin treatment. Although the mechanism of rifampin sen-
sitivity in the CarD-RID mutants is currently unclear, further in-
vestigations into this phenomenon will provide much-needed in-
sight into the mechanism of action of CarD regulation of
transcription and will serve as a platform for investigating the
possibility of increasing the potency of rifampin.
We had hypothesized that the effects of weakening the CarD/
RNAP interaction would be similar to the effects of decreasing
CarD protein levels. Surprisingly, phenotypic analyses revealed a
more complicated situation. For instance, the depletion of CarD
confers increased sensitivity to the fluoroquinolone ciprofloxacin
but not to rifampin, while mutants that weaken the CarD/RNAP
interaction display a different antibiotic-susceptibility profile. The
finding that ciprofloxacin susceptibility is unresponsive to
changes in the interaction of CarD with RNAP 1 but is sensitive
to CarD protein levels indicates that CarD has a function distinct
from binding RNAP. The unique sensitivity of the CarD RID mu-
tants to rifampin treatment further supports the idea that other
functional domains exist within CarD that retain activity in the
context of the RID mutant but not during CarD protein depletion.
In this case, we predict that when CarD binds the RNAP, it coun-
teracts another function of CarD that would make the bacteria
more sensitive to rifampin treatment. There are a number of ex-
amples in the literature of point mutants that inactivate one func-
tion of a protein but do not phenocopy the deletion mutant due to
the activity of another functional domain. For instance, one of our
groups recently showed that a mutation in the mycobacterial non-
homologous end-joining ligase D (LigD) that inactivates ligase
activity does not phenocopy theligD strain, because the scaffold-
ing function of the polymerase domain of LigD is still present (1,
2). We speculate that a similar situation is true for CarD, where
point mutations in the RID affect binding to RNAP 1 but leave
another function of CarD intact; thus, the point mutant does not
mimic CarD depletion.
The mycobacterial CarD RID comprises the 66 N-terminal
amino acids of the protein, while the C terminus remains com-
pletely uncharacterized. We believe that the C terminus of CarD
encodes an important functional domain since we are unable to
complement CarD depletion with the M. smegmatis TRCF RID
(22), indicating that RNAP binding is not sufficient for CarD ac-
tivity. Investigations into the function of the CarD C terminus are
under way and will hopefully shed light onto the elusive mode of
transcriptional regulation by CarD, as well as help reconcile the
phenotypic differences between CarD depletion and the disrup-
tion of the CarD/RNAP  interaction.
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